Brief: Kezar Life Sciences Announces Positive Topline Results From The MISSION Phase 2 Trial Evaluating Zetomipzomib For The Treatment Of Patients With Lupus Nephritis

Kezar Life Sciences

27/06/2022 21:38

June 27 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES ANNOUNCES POSITIVE TOPLINE RESULTS
FROM THE
MISSION PHASE 2 TRIAL EVALUATING ZETOMIPZOMIB FOR THE TREATMENT
OF PATIENTS WITH LUPUS NEPHRITIS
    * KEZAR LIFE SCIENCES INC - 6 OF 17 PATIENTS (35.2%)
ACHIEVED A
COMPLETE RENAL RESPONSE, INCLUDING A UPCR OF 0.5 OR LESS AT 6
MONTHS
    * KEZAR LIFE SCIENCES - ZETOMIPZOMIB CONTINUES TO
DEMONSTRATE A
FAVORABLE SAFETY & TOLERABILITY PROFILE FOR ADMINISTRATION OVER
6-MONTH TREATMENT PERIOD
    * KEZAR LIFE SCIENCES INC - ADDITIONALLY, EXPLORATORY
MEASURES OF
EXTRA-RENAL DISEASE ACTIVITY ASSOCIATED WITH SLE IMPROVED IN
PATIENTS COMPLETING TRIAL
    * KEZAR LIFE SCIENCES -11 OF 17 PATIENTS ACHIEVED OVERALL
RENAL
RESPONSE OF 50% OR GREATER REDUCTION IN URINE PROTEIN TO
CREATININE RATIO AT 6 MONTHS

Source text for Eikon:  ID:nBwc8LMZla 
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))